ClinicalTrials.gg
RecruitingNCT07351006Updated Sep 22, 2026

Exercise as Medicine: A Non-Pharmacological Approach to Menopausal Symptoms

An interventional study of Strength training and Dance-based training in Menopause Syndrome and Sleep Disturbance, sponsored by Linnaeus University. Recruiting at 1 site in Sweden. Open to female participants aged 45 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Linnaeus University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
45 Years to 55 Years
Sex
Female
01

Study summary

The aim of this clinical trial is to evaluate the effects of different forms of physical exercise in women experiencing menopausal symptoms. Specifically, the project investigates the effects of: (1) strength training on women's perceived menopausal symptoms; (2) dance-based exercise on women's perceived menopausal symptoms; and (3) adherence to structured, digital home-based exercise programs.

The following research questions will be addressed within the framework of the project:

Does regular strength training reduce women's perceived menopausal symptoms?

To what extent does strength training influence menopausal symptoms and sleep quality in women?

What is the level of adherence to a digital, home-based strength training program among women with menopausal symptoms?

Does regular dance-based physical activity reduce women's perceived menopausal symptoms?

To what extent does dance-based physical activity influence menopausal symptoms and sleep quality in women?

What is the level of adherence to a digital, home-based dance exercise program among women with menopausal symptoms?

Which exercise protocol-strength training or dance-based exercise-has the greatest effect on perceived menopausal symptoms?

The researchers will compare a digital, home-based strength training program with a digital, home-based dance exercise program, as well as with a control group, to determine which type of exercise has the greatest effect on menopausal symptoms and sleep quality.

Participants will:

Perform either dance-based exercise or strength training for 8 weeks, three times per week, following a structured program of approximately 30 minutes per session, or participate as part of the control group.

Complete validated questionnaires assessing menopausal health, including somatic, psychological, and sexual symptoms, as well as perceived quality of life and sleep quality, both before and after the intervention.

Maintain a training diary to monitor adherence and progression, including increases in training intensity

Read the detailed description

This clinical trial will be conducted as a randomized controlled trial, in which participants will be randomly assigned to either an intervention group or a control group. The study will begin with a pilot phase including 45 menopausal women, who will be randomly allocated to one of three groups: (1) strength training intervention (n = 15); (2) dance-based training intervention (n = 15); or (3) control group (n = 15).

Following completion of the pilot study, a full-scale intervention trial will be conducted. The sample size for the main study will be determined by a power calculation based on the results obtained from the pilot phase.

The study will begin with an assessment of participants' menopausal health, including somatic, psychological, and sexual symptoms, as well as perceived quality of life and sleep quality. These outcomes will be measured using the Menopause Rating Scale (MRS) and the Pittsburgh Sleep Quality Index (PSQI).The training protocols will be conducted over an 8-week period, with sessions performed three times per week according to a structured program lasting approximately 30 minutes per session. Two weeks after completion of the intervention, participants will be reassessed using the same instruments, with questionnaires distributed electronically via SurveyMonkey®.

The intervention will begin with a digital introductory meeting, during which participants will receive information materials on menopausal symptoms and a detailed review of the training program and study procedures. Participants in the control group will continue their usual daily activities without any prescribed intervention throughout the 8-week study period. Participants in the control group will be assessed using both instruments on two occasions, with an 8-week interval between assessments. Upon completion of the study, control group participants will be offered access to both intervention programs, as well as the results from Studies 1 and 2.

Throughout the study period, participants will be instructed not to introduce any additional forms of exercise or make changes to existing physical activity habits. The full-scale intervention is planned to be conducted over a 15-week period with a potentially larger sample size.

02

Conditions studied

  • Menopause Syndrome
  • Sleep Disturbance
03

In context

Lead sponsor

Linnaeus University is the lead sponsor of 29 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Biological female sex
  • Age 45-55 years
  • Experiencing menopausal symptoms, defined as irregular or altered menstruation plus at least one of the following:
  • Hot flashes or sweating
  • Sleep problems
  • Mood swings or depression
  • Dry mucous membranes
  • Recurrent urinary tract infections or overactive bladder
  • Joint pain
  • Decreased libido
  • Weight gain

Exclusion criteria

Exclusion Criteria:

  • Have taken medication or natural remedies for menopausal symptoms in the past 2 months
  • Menopause due to illness or surgical intervention
  • Medical conditions that contraindicate participation in the exercise intervention
  • Engaged in physical activity for ≥150 minutes per week, including ≥ 75 minutes at high intensity
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Strength training

    Strength training intervention.

    Other: Strength training

  • Experimental
    Dance-based training

    Dance-based training intervention.

    Other: Dance-based training

  • No intervention
    Control

    No intervention

Interventions

  • OtherStrength training

    The strength training intervention consists of an 8-week program performed 3 times per week, with sessions lasting \~30 minutes. Designed by a licensed physiotherapist, the program targets major muscle groups and includes a warm-up followed by structured exercises. Training uses body weight and simple household equipment, such as chairs and filled water bottles, at an intensity of 8-12 repetition maximum. Each exercise has three to four difficulty levels. Before starting, participants test and select an appropriate level for each exercise to ensure correct intensity. Participants perform at a level allowing at least eight repetitions and progress once they can complete more than twelve. This enables individualized, progressive training. After each session, participants record the difficulty level and number of repetitions in a training diary. For the full-scale intervention, exercise selection, intensity, and volume may be adjusted, and the program will be extended to 15 weeks.

  • OtherDance-based training

    Participants in the dance-based intervention will exercise three times per week at moderate intensity, following a structured 30-minute program performed individually at home via pre-recorded sessions. After each session, participants will complete a training diary and rate perceived exertion using the Borg RPE scale (6-20), targeting at least moderate intensity (RPE ≥ 14), adjusting effort accordingly. The program was developed and recorded by a licensed physiotherapist, pilot-tested with a small group, and reviewed by a supervising expert who provided feedback. Participants can ask questions and receive guidance on performing the exercises. For the full-scale intervention, exercise selection, intensity, and volume may be refined, and the program will be conducted over 15 weeks.

06

What researchers measure

Primary outcomes

  1. Menopause Rating Scale (MRS)

    The Menopause Rating Scale (MRS) consists of 11 items grouped into three dimensions: * Somatic Symptoms: Hot flashes, joint pain, and related physical complaints. * Psychological Symptoms: Depressive mood, irritability, anxiety, and similar issues. * Urogenital Symptoms: Bladder problems, vaginal dryness, and related concerns. Each item is rated on a 5-point Likert scale from 0 (not present) to 4 (very severe). The total score, calculated by summing all items, provides an overall measure of menopausal symptom severity. Thus, total score ranging from 0-44.

    Time frame: 2 times: 1) Baseline: Day 1 and 2) Post intervention: week 8

Secondary outcomes

  1. Pittsburgh Sleep Quality Index (PSQI)

    Sleep quality is assessed using the Pittsburgh Sleep Quality Index (PSQI), which evaluates seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Each component is scored from 0 to 3, and a global score is calculated by summing the components. Higher scores indicate poorer sleep quality. The Pittsburgh Sleep Quality Index (PSQI) generates a global score ranging from 0 to 21, where a score greater than 5 typically indicates poor sleep quality. This threshold serves as a clinical benchmark, with higher scores correlating with increased severity of sleep disturbances.

    Time frame: 2 times: 1) Baseline: Day 1 and 2) Post intervention: week 8

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for May 2027, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Jan 20, 2026
StartActual
Nov 1, 2025
Primary completionEst.
May 2027
CompletionEst.
Dec 2027
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07351006
Lead sponsor
Linnaeus University
Responsible party
Sofia Ryman Ryman Augustsson (Associate Professor, Linnaeus University) — Principal investigator
First posted
Jan 20, 2026
Start date
Nov 1, 2025
Primary completion
May 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion